Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606273 | 1.00 | CETP (0.40) | CETPPKM | |
| SCHEMBL7756545 | 0.84 | CETP (0.36) | CETPPKM | |
| SCHEMBL7756535 | 0.84 | CETP (0.36) | CETPPKM | |
| SCHEMBL22108710 | 0.79 | — | — | |
| SCHEMBL310531 | 0.79 | — | — | |
| SCHEMBL10339721 | 0.79 | CETP (0.43) | CETPPKM | |
| SCHEMBL310532 | 0.79 | — | — | |
| SCHEMBL31685193 | 0.77 | CETP (0.42) | CETPPKM | |
| SCHEMBL7750637 | 0.76 | ALDH1A1 (0.39) | CETPPKM | |
| SCHEMBL7750633 | 0.76 | ALDH1A1 (0.39) | CETPPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | claimed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | claimed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
| EP-0992486-B1 | Tetralin compound, liquid crystal material, and liquid crystal composition | MITSUI CHEMICALS INC (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-6117359-A | A FERROELECTRIC LIQUID CRYSTAL, AN ANTIFERROELECTRIC LIQUID CRYSTAL; OPERATING WIDE TEMPERATURE RANGE, A HIGH SWITCHING SPEED AND A SMALL CONSUMPTION OF ELECTRIC POWER, A STABLE CONTRAST | MITSUI CHEMICALS INC (JP) | 2000-09-12 | — | — | US | disclosed |
| EP-0992486-A2 | Tetralin compound, liquid crystal material, and liquid crystal composition | Mitsui Chemicals, Inc. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | CETP 205/4885PKM 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.